Analysts Issue Forecasts for Moderna FY2029 Earnings

Moderna, Inc. (NASDAQ:MRNAFree Report) – Investment analysts at Brookline Capital Management issued their FY2029 earnings estimates for shares of Moderna in a note issued to investors on Monday, January 13th. Brookline Capital Management analyst L. Cann forecasts that the company will post earnings per share of $22.02 for the year. The consensus estimate for Moderna’s current full-year earnings is ($9.30) per share.

Moderna (NASDAQ:MRNAGet Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter last year, the firm earned ($1.39) earnings per share. The firm’s revenue was up 3.8% compared to the same quarter last year.

Other research analysts have also recently issued research reports about the company. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research report on Friday, November 8th. Hsbc Global Res upgraded shares of Moderna from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. Royal Bank of Canada restated a “sector perform” rating and set a $75.00 target price on shares of Moderna in a research report on Thursday, September 19th. JPMorgan Chase & Co. reduced their price target on shares of Moderna from $59.00 to $45.00 and set an “underweight” rating for the company in a research report on Tuesday, November 26th. Finally, Jefferies Financial Group lowered their price target on Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a report on Tuesday, October 15th. Four equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Moderna currently has a consensus rating of “Hold” and an average target price of $76.68.

Get Our Latest Stock Report on Moderna

Moderna Stock Up 0.9 %

MRNA opened at $34.77 on Wednesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. Moderna has a 12 month low of $31.94 and a 12 month high of $170.47. The stock has a market capitalization of $13.38 billion, a P/E ratio of -5.97 and a beta of 1.60. The business has a 50 day simple moving average of $41.44 and a 200-day simple moving average of $67.56.

Insiders Place Their Bets

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the transaction, the insider now directly owns 19,717 shares in the company, valued at $843,690.43. This represents a 6.71 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold a total of 2,664 shares of company stock valued at $115,210 in the last quarter. 15.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Moderna

Several institutional investors and hedge funds have recently bought and sold shares of MRNA. Acadian Asset Management LLC purchased a new position in shares of Moderna in the 2nd quarter worth about $900,000. Ashton Thomas Private Wealth LLC purchased a new stake in Moderna during the 2nd quarter worth $26,000. Dai ichi Life Insurance Company Ltd increased its holdings in Moderna by 187.1% in the 2nd quarter. Dai ichi Life Insurance Company Ltd now owns 7,673 shares of the company’s stock valued at $911,000 after purchasing an additional 5,000 shares in the last quarter. Envestnet Asset Management Inc. raised its position in Moderna by 78.7% in the second quarter. Envestnet Asset Management Inc. now owns 109,733 shares of the company’s stock valued at $13,031,000 after purchasing an additional 48,316 shares during the period. Finally, WINTON GROUP Ltd acquired a new position in shares of Moderna during the second quarter worth about $426,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Company Profile

(Get Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Further Reading

Earnings History and Estimates for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.